The approval is supported by data from the phase 3 VOLGA trial.
Feature|Articles|September 29, 2025
What urologists can expect in Q4 of 2025
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A comprehensive guide to the key regulatory decisions and conferences slated for the last few months of the year.
Advertisement
Advertisement
As we enter the final months before the end of 2025, we reflect on the notable advances that have already shifted the landscape in urologic care. Looking back at this year, we saw notable approvals across bladder cancer, prostate cancer, and benign conditions.
Related to this article
Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.
Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
Advertisement
Advertisement